Neurocrine Biosciences (NBIX) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Which has more risk and volatility, ALNY or NBIX?

Alnylam Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Is ALNY or NBIX more profitable?

Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Neurocrine Biosciences	14.49%	13.38%	9.73%

Does the MarketBeat Community prefer ALNY or NBIX?

Alnylam Pharmaceuticals received 123 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.68% of users gave Neurocrine Biosciences an outperform vote while only 76.32% of users gave Alnylam Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1167 76.32%	Underperform Votes 362 23.68%
Neurocrine Biosciences	Outperform Votes 1044 77.68%	Underperform Votes 300 22.32%

Does the media refer more to ALNY or NBIX?

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Neurocrine Biosciences and 20 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.21 beat Neurocrine Biosciences' score of 1.13 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Neurocrine Biosciences	18 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, ALNY or NBIX?

Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.35B	15.84	-$278.16M	-$2.09	-136.51
Neurocrine Biosciences	$2.41B	4.96	$341.30M	$2.95	41.02

Do institutionals & insiders hold more shares of ALNY or NBIX?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer ALNY or NBIX?

Alnylam Pharmaceuticals currently has a consensus price target of $319.17, suggesting a potential upside of 11.87%. Neurocrine Biosciences has a consensus price target of $162.00, suggesting a potential upside of 33.86%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Neurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.